Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2407338 | Vaccine | 2008 | 5 Pages |
Abstract
This report describes the safety observations following administration of a polyvalent DNA prime–protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein + QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jeffrey S. Kennedy, Mary Co, Sharone Green, Karen Longtine, Jaclyn Longtine, Melissa A. O’Neill, Janice P. Adams, Alan L. Rothman, Qiao Yu, Renita Johnson-Leva, Ranajit Pal, Shixia Wang, Shan Lu, Phillip Markham,